14-day Premium Trial Subscription Try For FreeTry Free
$1.15
+0.0700 (+6.48%)
At Close: May 03, 2024
Forecast Earnings Fundamentals Insider Trading Signals Historical Prices Predictions News Profile
Date Action Amount Person Type
Mar 11, 2024 Sell 14 235 Taveras Arthur Common Stock
Mar 11, 2024 Sell 49 678 Ragan Paula Common Stock
Mar 11, 2024 Sell 52 500 Mostafa Adam S. Common Stock
Mar 11, 2024 Sell 15 409 Dibiase Mary Common Stock
Feb 13, 2024 Buy 180 816 Arbet-engels Christophe Stock Appreciation Right
Feb 13, 2024 Buy 475 831 Arbet-engels Christophe Stock Appreciation Right
Feb 13, 2024 Buy 523 414 Mostafa Adam S. Stock Appreciation Right
Feb 13, 2024 Buy 428 248 Dibiase Mary Stock Appreciation Right
Feb 13, 2024 Buy 1 189 578 Ragan Paula Stock Appreciation Right
Feb 13, 2024 Buy 523 414 Baldry Mark Stock Appreciation Right
Feb 13, 2024 Buy 428 248 Taveras Arthur Stock Appreciation Right
Feb 12, 2024 Sell 3 683 Dibiase Mary Common Stock
Feb 12, 2024 Sell 787 Taveras Arthur Common Stock
Feb 12, 2024 Sell 21 695 Ragan Paula Common Stock
Feb 12, 2024 Sell 27 721 Mostafa Adam S. Common Stock
Nov 03, 2023 Sell 39 906 Ragan Paula Common Stock
Nov 01, 2023 Sell 199 531 Ragan Paula Common Stock
Nov 01, 2023 Sell 230 645 Mostafa Adam S. Common Stock
Nov 01, 2023 Sell 67 695 Dibiase Mary Common Stock
Nov 01, 2023 Sell 10 257 Baldry Mark Common Stock
Nov 01, 2023 Sell 67 695 Taveras Arthur Common Stock
Oct 31, 2023 Buy 230 645 Mostafa Adam S. Common Stock
Oct 31, 2023 Buy 34 947 Baldry Mark Common Stock
Oct 31, 2023 Buy 230 645 Taveras Arthur Common Stock
Oct 31, 2023 Buy 532 081 Ragan Paula Common Stock
Oct 31, 2023 Buy 230 645 Dibiase Mary Common Stock
Oct 16, 2023 Buy 90 000 Woods Keith Common Stock
Oct 16, 2023 Buy 0 Woods Keith
Sep 08, 2023 Sell 2 642 Dibiase Mary Common Stock
Aug 31, 2023 Buy 1 250 000 Arbet-engels Christophe Stock Option (right to buy)
Aug 18, 2023 Buy 25 000 Wyzga Michael S Common Stock
Aug 16, 2023 Buy 0 Arbet-engels Christophe
Aug 10, 2023 Sell 130 056 Stewart Murray Common Stock
Aug 09, 2023 Buy 269 893 Stewart Murray Common Stock
Jun 30, 2023 Sell 464 Dibiase Mary Common Stock
Jun 30, 2023 Sell 2 641 Mostafa Adam S. Common Stock
Jun 23, 2023 Sell 857 Dibiase Mary Common Stock
Jun 23, 2023 Sell 5 417 Mostafa Adam S. Common Stock
Jun 23, 2023 Sell 6 724 Ragan Paula Common Stock
Jun 15, 2023 Sell 857 Dibiase Mary Common Stock
Jun 15, 2023 Sell 5 417 Mostafa Adam S. Common Stock
Jun 15, 2023 Sell 6 724 Ragan Paula Common Stock
Jun 13, 2023 Buy 45 000 Aliski William Common Stock
Jun 13, 2023 Buy 45 000 Bridger Gary Common Stock
Jun 13, 2023 Buy 45 000 Mcgirr David W J Common Stock
Jun 13, 2023 Buy 45 000 Wyzga Michael S Common Stock
Jun 13, 2023 Buy 45 000 De Craecker Francoise Common Stock
Jun 13, 2023 Buy 45 000 Lawton Alison Frances Common Stock
May 31, 2023 Sell 6 292 Ragan Paula Common Stock
Mar 10, 2023 Sell 18 192 Dibiase Mary Common Stock
Mar 10, 2023 Sell 52 500 Mostafa Adam S. Common Stock
Mar 10, 2023 Sell 16 806 Taveras Arthur Common Stock
Mar 10, 2023 Sell 49 678 Ragan Paula Common Stock
Feb 13, 2023 Sell 928 Taveras Arthur Common Stock
Feb 13, 2023 Sell 4 348 Dibiase Mary Common Stock
Feb 13, 2023 Sell 27 721 Mostafa Adam S. Common Stock
Feb 13, 2023 Sell 21 695 Ragan Paula Common Stock
Nov 07, 2022 Buy 1 350 000 Dibiase Mary Stock Appreciation Right
Nov 07, 2022 Buy 1 350 000 Mostafa Adam S. Stock Appreciation Right
Nov 07, 2022 Buy 1 000 000 Taveras Arthur Stock Appreciation Right
Nov 07, 2022 Buy 3 438 335 Ragan Paula Stock Appreciation Right
Nov 03, 2022 Buy 341 000 Baldry Mark Stock Option (right to buy)
Nov 03, 2022 Buy 0 Baldry Mark
Nov 03, 2022 Buy 0 Baldry Mark
Aug 17, 2022 Sell 8 334 Meisner Derek M Common Stock
Aug 17, 2022 Sell 8 334 Meisner Derek M Common Stock
Aug 17, 2022 Sell 1 713 Dibiase Mary Common Stock
Aug 17, 2022 Sell 13 448 Ragan Paula Common Stock
Aug 17, 2022 Sell 10 834 Mostafa Adam S. Common Stock
Jun 30, 2022 Sell 2 641 Mostafa Adam S. Common Stock
Jun 30, 2022 Sell 1 578 Dibiase Mary Common Stock
Jun 24, 2022 Sell 5 416 Mostafa Adam S. Common Stock
Jun 24, 2022 Sell 856 Dibiase Mary Common Stock
Jun 24, 2022 Sell 6 724 Ragan Paula Common Stock
Jun 24, 2022 Sell 4 166 Meisner Derek M Common Stock
Jun 24, 2022 Sell 4 166 Meisner Derek M Common Stock
Jun 16, 2022 Sell 5 416 Mostafa Adam S. Common Stock
Jun 16, 2022 Sell 6 724 Ragan Paula Common Stock
Jun 16, 2022 Sell 856 Dibiase Mary Common Stock
Jun 16, 2022 Sell 4 166 Meisner Derek M Common Stock
Jun 16, 2022 Sell 4 166 Meisner Derek M Common Stock
Jun 06, 2022 Buy 6 667 Bridger Gary Common Stock
Jun 06, 2022 Buy 6 667 Lawton Alison Frances Common Stock
Jun 06, 2022 Buy 6 667 Wyzga Michael S Common Stock
Jun 06, 2022 Buy 6 667 De Craecker Francoise Common Stock
Jun 06, 2022 Buy 6 667 Stewart Murray Common Stock
Jun 06, 2022 Buy 6 667 Aliski William Common Stock
Jun 06, 2022 Buy 6 667 Mcgirr David W J Common Stock
Jun 03, 2022 Sell 6 292 Ragan Paula Common Stock
Mar 01, 2022 Buy 105 000 Dibiase Mary Common Stock
Mar 01, 2022 Buy 220 789 Ragan Paula Common Stock
Mar 01, 2022 Buy 97 000 Taveras Arthur Common Stock
Mar 01, 2022 Buy 105 000 Mostafa Adam S. Common Stock
Mar 01, 2022 Buy 97 000 Cadavid Diego Common Stock
Mar 01, 2022 Buy 105 000 Meisner Derek M Common Stock
Feb 11, 2022 Sell 27 721 Mostafa Adam S. Common Stock
Feb 11, 2022 Sell 15 909 Meisner Derek M Common Stock
Feb 11, 2022 Sell 12 545 Dibiase Mary Common Stock
Feb 11, 2022 Sell 928 Taveras Arthur Common Stock
Feb 11, 2022 Sell 21 695 Ragan Paula Common Stock
JSON CSV
INSIDER POWER
74.361
Last 100 transactions
Buy: 15 169 198 | Sell: 1 336 024 (Shares)

Based on the 100 latest insides trades, we have calculated the insider power to be positive at a ratio of 74.361.

In total, the insiders bought 15 169 198 and sold 1 336 024 XFOR shares in the last 100 trades.

Click to get the best stock tips daily for free!

About X4 Pharmaceuticals Inc.

X4 Pharmaceuticals. X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and my... XFOR Profile

Golden Star

Ticker Date Change Price
CVBF May 01 2.75% $16.75
FTSL May 01 0.282% $46.03
EQC Apr 30 0.694% $18.72
HRB Apr 30 0.635% $47.23
BSCQ Apr 30 0.576% $19.09
BSJP Apr 29 0.306% $22.91
LYG Apr 29 1.56% $2.56
ORA Apr 29 4.68% $64.48
DHT Apr 24 3.10% $11.28
LPLA Apr 19 3.12% $262.59
Unlock

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT